ODG
RXRX icon

O'Dell Group’s Recursion Pharmaceuticals RXRX Stock Holding History

O'Dell Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,200
Closed -$11.8K – 396
2023
Q4 		$11.8K Buy
+1,200
New +$8.56K ﹤0.01% 335
2023
Q3 		– Sell
-1,175
Closed -$8.78K – 392
2023
Q2 		$8.78K Buy
+1,175
New +$8.22K ﹤0.01% 353
2022
Q4 		– Sell
-1,175
Closed -$13K – 328
2022
Q3 		$13K Buy
+1,175
New +$11.9K ﹤0.01% 272

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

O'Dell Group's RXRX Position: Q1 2024 in Review

O'Dell Group sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 1,200 shares — an estimated $11.8K sold.

O'Dell Group first reported a position in RXRX in Q3 2022 and held it in 3 quarters. The position peaked at $13K in Q3 2022. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

  • O'Dell Group reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • O'Dell Group sold 1,200 Recursion Pharmaceuticals shares in Q1 2024, an estimated $11.8K.
  • O'Dell Group first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • O'Dell Group's Recursion Pharmaceuticals position peaked at $13K in Q3 2022.
  • 249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.